Subtype
Hepatopancreatobiliary Carcinoma
CI-CAN-00002859Explore in graph →
1,361 active trials21 approved drugs69 evidence items
- NCIt
- C214986
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002859Explore in graph →
Clinical trials
5,154 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (647)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05988918 | Multicenter Trial of ESK981 in Patients With Select Solid Tumors | active not recruiting | Phase 2 | 17 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT06922591 | Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients | recruiting | Phase 1 / Phase 2 | 183 | Tango Therapeutics, Inc.INDUSTRY | 1 | May 14, 2026 | clinicaltrials |
| NCT07493044 | An Open-Label, Phase I Clinical Trial of Super CAR-T With GPC3-Positive Advanced Hepatocellular Carcinoma | recruiting | Phase 1 | 15 | Guangzhou FineImmune Biotechnology Co., LTD.INDUSTRY | 1 | May 14, 2026 | clinicaltrials |
| NCT07557225 | 18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors | recruiting | N/A | 200 | Peking University First HospitalOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT07581769 | Radiomics Subtyping to Guide Surgery vs. Maintenance Therapy After HCC Downstaging | active not recruiting | — | 500 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT03017326 | Paediatric Hepatic International Tumour Trial(PHITT) | active not recruiting | Phase 3 | 450 | University of BirminghamOTHER | 14 | May 13, 2026 | clinicaltrials |
| NCT06058663 | Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma | recruiting | Phase 1 | 16 | Mayo ClinicOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT06549751 | MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer(PANACEA) | not yet recruiting | Phase 1 | 38 | Marker Therapeutics, Inc.INDUSTRY | 1 | May 13, 2026 | clinicaltrials |
| NCT06735560 | Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, BTC or NEN(ELEGANCE) | recruiting | N/A | 60 | Nantes University HospitalOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT07012798 | FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma | recruiting | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT07583316 | A Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A*02:01 Bispecific T-Cell Engager, in Patients With Solid Tumors | not yet recruiting | Phase 1 | 192 | Corregene Biotechnology Co., LtdINDUSTRY | 1 | May 13, 2026 | clinicaltrials |
| NCT07583771 | A Phase Ⅰ Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma | not yet recruiting | Phase 1 | 186 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | May 13, 2026 | clinicaltrials |
| NCT07584018 | The DoHAICs Study Expansion Phase | not yet recruiting | Phase 2 | 90 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | May 13, 2026 | clinicaltrials |
| NCT07584317 | AI-Based Multimodal Integration for Tumor Microenvironment Analysis and Response Prediction in HCC Treated With TACE Plus Immunotherapy and Targeted Therapy (CHANCE2601) | not yet recruiting | — | 1,170 | Gao-jun TengOTHER | 0 | May 13, 2026 | clinicaltrials |
| NCT07081633 | Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma(TREMENDOUS-2) | active not recruiting | Phase 2 | 114 | AstraZenecaINDUSTRY | 2 | May 12, 2026 | clinicaltrials |
| NCT07413354 | Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma | recruiting | Phase 2 | 94 | Tongji HospitalOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT07580261 | YMN-A02 for Advanced Primary Hepatocellular Carcinoma. | not yet recruiting | Phase 1 | 10 | West China HospitalOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT07582419 | Hybrid Deep Learning Integrating Multimodal CEUS and Enhanced MRI to Optimize Early-Stage HCC Treatment Decisions(HDL-CEUS-MRI) | not yet recruiting | — | 1,424 | The First Hospital of Jilin UniversityOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT06794073 | Efficacy and Safety of Multimodal Ablation Combined With PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of Unresectable Primary Hepatocellular Carcinoma: A Single-Arm, Single-Center Clinical Study | recruiting | N/A | 17 | Shanghai Zhongshan HospitalOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT07150624 | The Treatment of Liver Injury After Liver Resection With Polyene Phosphatidylcholine | recruiting | Phase 4 | 96 | Anhui Provincial HospitalOTHER_GOV | 1 | May 11, 2026 | clinicaltrials |
| NCT07226869 | Computer Guided Microwave Liver Ablation(MWA Sim) | recruiting | N/A | 84 | NE Scientific INCINDUSTRY | 1 | May 11, 2026 | clinicaltrials |
| NCT07532590 | Patients With Pancreatic Tumor: Use of an App to Monitor Progress in a Simple and Intuitive Way by Periodically Completing Targeted Questionnaires and Providing Educational and Informational Content (PancreasPlus). | recruiting | N/A | 185 | Casa di Cura Dott. PederzoliOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT04331041 | Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma | active not recruiting | Phase 2 | 42 | Washington University School of MedicineOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT04627246 | Personalized Vaccine With SOC Chemo Followed by Nivo in Pancreatic Cancer | active not recruiting | Phase 1 | 14 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT06852820 | 68Ga-PSMA-11 PET-directed Radioligand Therapy in Metastatic Hepatocellular Carcinoma (HCC) | recruiting | Phase 2 | 10 | Melissa LumishOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT07436312 | Impact of Consumption of Ultra-processed Foods in Individuals at High Risk of Cancer(U-TRANS) | recruiting | N/A | 170 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT07164313 | A Study of ZW251 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 100 | Zymeworks BC Inc.INDUSTRY | 6 | May 7, 2026 | clinicaltrials |
| NCT07554560 | Nutrition Intervention for Pancreatic Cancer | recruiting | N/A | 18 | Children's Hospital of PhiladelphiaOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT01840592 | Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib | active not recruiting | Phase 2 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT06239194 | Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 285 | ModeX Therapeutics, An OPKO Health CompanyINDUSTRY | 1 | May 6, 2026 | clinicaltrials |
| NCT06441747 | Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP) | recruiting | Phase 2 | 40 | Australasian Gastro-Intestinal Trials GroupNETWORK | 1 | May 6, 2026 | clinicaltrials |
| NCT07570849 | Chidamide Combined With Chemotherapy and Immunotherapy as First-line Treatment for Advanced Intrahepatic Cholangiocarcinoma | recruiting | Phase 2 | 35 | Shanghai Zhongshan HospitalOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT03107416 | Delivering a Diuretic Into the Liver Artery Followed by Plugging up the Artery to Starve Out Liver Cancer Cells | active not recruiting | Phase 1 / Phase 2 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT04881487 | Additional Treatment for Isolated Local Pancreatic Cancer Recurrence Using Stereotactic Body Radiation Therapy(ARCADE) | recruiting | N/A | 174 | UMC UtrechtOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT06228599 | Molecular Profile-related Individualized Targeted Therapy in Resected Pancreatic Cancer With High-Risk of Cancer Recurrence(PROTECT-PANC) | recruiting | N/A | 40 | Medical College of WisconsinOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07014150 | Neoadjuvant Therapy of Iparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular Carcinoma | recruiting | Phase 2 | 33 | Peking Union Medical College HospitalOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07122089 | Evaluation of SIRT Followed by Immunotherapy for Treatment of Hepatocellular Carcinoma With Portal Vein Thrombosis(IOSPHERE) | recruiting | Phase 2 | 80 | Center Eugene MarquisOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07226063 | Maintenance Zanzalintinib and Durvalumab in Participants With Advanced Hepatocellular Cancer | not yet recruiting | Phase 2 | 16 | Amit MahipalOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07354919 | Axelopran for Advanced Cancer in Patients Receiving Opioids(AxeCan) | recruiting | Phase 2 | 34 | HealthPartners InstituteOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07566897 | A Phase I Study to Evaluate the Safety and Efficacy of L19IL2 in Combination With Ruxolitinib in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 | 96 | Philogen S.p.A.INDUSTRY | 1 | May 5, 2026 | clinicaltrials |
| NCT07568457 | Social Determinants of Health HCC Trial | not yet recruiting | N/A | 75 | University of Southern CaliforniaOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT03482102 | Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer | active not recruiting | Phase 2 | 37 | Massachusetts General HospitalOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT05296421 | Investigating Targetable Metabolic Pathways Sustaining Pancreatic Cancer | recruiting | N/A | 16 | Rutgers, The State University of New JerseyOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT05933265 | Study of LP-184 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 64 | Lantern Pharma Inc.INDUSTRY | 1 | May 4, 2026 | clinicaltrials |
| NCT06015659 | ZN-c3 + Gemcitabine in Pancreatic Cancer | active not recruiting | Phase 2 | 12 | Brandon Huffman, MDOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT07565415 | Nanocrystalline Megestrol Acetate Versus Placebo for Anorexia in Patients With Unresectable Hepatocellular Carcinoma Receiving TACE Combined With Targeted and Immunotherapy | not yet recruiting | Phase 2 | 88 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT02838836 | Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers | recruiting | — | 620 | University of Missouri-ColumbiaOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT06050317 | Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer | recruiting | Phase 2 | 25 | Shandong Cancer Hospital and InstituteOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07030140 | Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma | recruiting | Phase 2 | 38 | Jinbo YueOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07099547 | Study of ZG005 in Combination With Platinum-Based Chemotherapy in Participants With Advanced Biliary Tract Carcinoma | recruiting | Phase 2 | 60 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | May 1, 2026 | clinicaltrials |
Data updated 24 days agoSource updated May 14, 2026source: clinicaltrials